指南与共识血栓与止血贫血与红细胞疾病

遗传性出血性毛细血管扩张症出血的术语、定义和结局标准标准化:国际共识报告

Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report.
指南 / 共识 · Am J Hematol · 2025-07-15

遗传性出血性毛细血管扩张症(HHT)缺乏统一的出血严重程度定义和结局标准,阻碍临床研究。Cure HHT基金会全球研究与医学顾问委员会召集国际专家、患者及倡导者,基于2025年1月7日Ovid MEDLINE系统检索证据,制定出血和贫血的标准术语、定义及严重程度分类,供监管机构、研究者和制药业采用。

要点

  • HHT出血术语、定义和结局标准缺乏共识,阻碍临床研究与治疗开发。
  • 国际共识报告制定HHT出血和贫血的标准术语、定义及严重程度分类。
  • 共识建议监管机构、研究者和制药业在临床试验和队列研究中采用这些标准。

核心结论

  • HHT出血和贫血的标准术语、定义及严重程度分类应被监管机构、研究者和制药业在干预性临床试验和队列研究中采用。

研究设计与样本

  • Cure HHT基金会全球研究与医学顾问委员会召集HHT临床研究者、外部专家、患者及患者倡导者召开会议制定共识。
  • 证据通过Ovid MEDLINE两种检索策略系统识别和评估,检索于2025年1月7日进行。

主要发现

  • HHT是全球第二常见的遗传性出血性疾病,约每5000人中有1人患病。
  • 数十年来缺乏改善疾病的有效止血药物后,针对HHT的研发终于开始。
  • 抗血管生成药物重定位和新型HHT特异性疗法的开发使比较性临床试验预计将在未来开展。

关键数值与推荐

  • 共识定义了HHT出血和贫血的结局及严重程度分类的标准术语和定义。
  • 共识标准应用于干预性临床试验和队列研究的开发与实施,以改善临床试验间可比性。

临床怎么用

  • 共识建议监管机构、研究者和制药业在干预性临床试验和队列研究中采用这些标准。
  • 共识旨在促进临床医生与研究者之间的沟通、改进治疗指南开发,并为监管机构提供标准化框架。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease-modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies. However, the lack of consensus on standardized severity definitions, outcome criteria, and terminology remains a major obstacle to clinical investigation and therapeutic development in HHT. Additionally, with the ongoing repurposing of antiangiogenic agents and emerging development of novel HHT-specific therapies, comparative clinical trials are expected in the future. Therefore, to end the problematic heterogeneity hindering these efforts, the Global Research and Medical Advisory Board (GRMAB) of the Cure HHT Foundation, an international group of recognized HHT experts, convened a conference of expert HHT clinician-investigators from within GRMAB as well as invited external experts in HHT and bleeding disorders generally, patients with HHT, and patient advocates to define standard terminology and definitions for outcomes and severity classification for bleeding and anemia in HHT. These criteria and definitions should be adopted by regulators, investigators, and the pharmaceutical industry in the development and performance of interventional clinical trials and cohort studies to allow improved comparability between clinical trials, facilitate communication between clinicians and investigators, improve therapeutic guideline development, and provide a standardized framework for regulatory agencies. SEARCH STRATEGY AND SELECTION CRITERIA: Evidence for this report was systematically identified and evaluated utilizing two search strategies in Ovid MEDLINE, described in full detail in the Appendix, pp.4-13. The searches were conducted on January 7, 2025. The titles and abstracts of each record were reviewed, and the inclusion criteria were applied to all search results to identify full text articles to be retrieved for further review. All retrieved full texts were then reviewed to reach a final determination if a study met the inclusion criteria. Included references were then compiled into evidence tables, which were then utilized by the International Consensus Report Working Group throughout the development of report recommendations.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Al-Samkari H, Kasthuri RS, Mager HJ, et al. Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report. Am J Hematol. 2025. PMID: 40662351. doi:10.1002/ajh.70011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。